SKAN Group AGFRA:7VG +2.61%62 Return-on-Tangible-Equity is 36.99% as of Dec. 2025, which is 212% above its 10-year median of 11.86. GuruFocus rates FRA:7VG with a GF Score™ of 62/100 and a GF Value™ of €90.91 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 756 Medical Devices & Instruments companies, SKAN Group AG ranks better than 67.59% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. SKAN Group AG's annualized net income for the quarter that ended in Dec. 2025 was €54.0 Mil. SKAN Group AG's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €145.8 Mil. Therefore, SKAN Group AG's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 36.99%.
The historical rank and industry rank for SKAN Group AG's Return-on-Tangible-Equity or its related term are showing as below:
FRA:7VG'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.48 Med: 11.86 Max: 21.62
Current: 10.48
During the past 6 years, SKAN Group AG's highest Return-on-Tangible-Equity was 21.62%. The lowest was 10.48%. And the median was 11.86%.
FRA:7VG's Return-on-Tangible-Equity is ranked better than 67.59% of 756
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs FRA:7VG: 10.48
SKAN Group AG (FRA:7VG) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
SKAN Group AG Return-on-Tangible-Equity Related Terms
SKAN Group AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for SKAN Group AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7VG vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, SKAN Group AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SKAN Group AG Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SKAN Group AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where SKAN Group AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 36.99% mean?
SKAN Group AG (FRA:7VG) has a Return-on-Tangible-Equity of 36.99% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SKAN Group AG and its competitors. This is 212% above median its historical median of 11.86. Over the past decade, SKAN Group AG's Return-on-Tangible-Equity has ranged from 10.48 to 21.62. According to the industry distribution chart, SKAN Group AG ranks #245 out of 756 companies in the Medical Devices & Instruments industry, placing it in the top 32.4%.
Is SKAN Group AG's Return-on-Tangible-Equity too high?
SKAN Group AG's current Return-on-Tangible-Equity of 36.99% is 212% above median its 10-year median of 11.86. Over the past 10 years, this metric has ranged from a low of 10.48 to a high of 21.62. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. SKAN Group AG's value of 36.99% is 806.6% above this industry median. Based on the distribution chart, SKAN Group AG ranks #245 out of 756 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SKAN Group AG has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SKAN Group AG's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, SKAN Group AG ranks #245 out of 756 companies for Return-on-Tangible-Equity. This puts SKAN Group AG in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.08. SKAN Group AG's value of 36.99% is 806.6% above this benchmark. Historically, SKAN Group AG's own Return-on-Tangible-Equity has ranged from 10.48 to 21.62 over the past decade. While the company's 10-year median is 11.86 vs. the industry median of 4.08, SKAN Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 756 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SKAN Group AG's current Return-on-Tangible-Equity of 36.99% is 806.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SKAN Group AG and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SKAN Group AG's current Return-on-Tangible-Equity is 36.99%, which is 212% above median its own 10-year median of 11.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SKAN Group AG stock overvalued right now?
Based on GuruFocus' analysis, SKAN Group AG (FRA:7VG) is currently considered Significantly Undervalued. The stock's GF Value™ is €90.91, compared to a current price of €59.00 — trading 35.1% below its estimated fair value. The current Return-on-Tangible-Equity is 36.99%, which is 212% above median its 10-year median of 11.86 and 806.6% above the Medical Devices & Instruments industry median of 4.08. SKAN Group AG's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For SKAN Group AG (FRA:7VG), the current Return-on-Tangible-Equity is 36.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SKAN Group AG (FRA:7VG) Overvalued in 2026?
Based on GuruFocus' analysis, SKAN Group AG stock appears to be undervalued.
The current stock price of €59.00 is trading 35.1% below its estimated GF Value™ of €90.91.
GuruFocus considers SKAN Group AG to be Significantly Undervalued.
Key valuation signals for FRA:7VG:
Return-on-Tangible-Equity: 36.99% (212% above median its 10-year median of 11.86)
GF Value™: €90.91 vs. price of €59.00 (35.1% below fair value)
Industry Position: 806.6% above the Medical Devices & Instruments median (#245 of 756)
No single metric tells the full story. See the FRA:7VG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SKAN Group AG is a market and technological company for isolators, cleanroom devices, and decontamination processes for the aseptic production of biopharmaceutical substances. The company offers its customers process support, services, and consumables. Its products include biological indicators, isolators, Laboratory/cleanroom equipment, laminar flow, safety workbenches, transfer systems, and others. The Firm has three operating segments: Equipment & solutions, Services & Consumables, and Other. The company generates the majority of its revenue from the Equipment & solutions segment. Geographically, the company derives revenue from Asia, Europe, Americas, and Other regions.
62GF Score
Get the complete analysis for FRA:7VG
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7VG has been successfully added to your 
